Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2010 1
2011 1
2012 2
2015 1
2020 1
2021 1
2023 1
2024 1
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
HIV drug resistance among adults initiating antiretroviral therapy in Uganda.
Watera C, Ssemwanga D, Namayanja G, Asio J, Lutalo T, Namale A, Sanyu G, Ssewanyana I, Gonzalez-Salazar JF, Nazziwa J, Nanyonjo M, Raizes E, Kabuga U, Mwangi C, Kirungi W, Musinguzi J, Mugagga K, Mbidde EK, Kaleebu P. Watera C, et al. Among authors: namayanja g. J Antimicrob Chemother. 2021 Aug 12;76(9):2407-2414. doi: 10.1093/jac/dkab159. J Antimicrob Chemother. 2021. PMID: 33993252 Free PMC article.
Scale-Up of HIV Antiretroviral Therapy and Estimation of Averted Infections and HIV-Related Deaths - Uganda, 2004-2022.
Dirlikov E, Kamoga J, Talisuna SA, Namusobya J, Kasozi DE, Akao J, Birabwa E, Ward JA, Elur B, Shiraishi RW, Corcoran C, Vasireddy V, Nelson R, Nelson LJ, Borgman M, Magongo EN, Kisaakye LN, Katureebe C, Kirungi W, Musinguzi J; PEPFAR Uganda. Dirlikov E, et al. MMWR Morb Mortal Wkly Rep. 2023 Jan 27;72(4):90-94. doi: 10.15585/mmwr.mm7204a2. MMWR Morb Mortal Wkly Rep. 2023. PMID: 36701255 Free PMC article.
Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda.
Kaleebu P, Kirungi W, Watera C, Asio J, Lyagoba F, Lutalo T, Kapaata AA, Nanyonga F, Parry CM, Magambo B, Nazziwa J, Nannyonjo M, Hughes P, Hladik W, Ruberantwari A, Namuwenge N, Musinguzi J, Downing R, Katongole-Mbidde E; HIV Drug Resistance Working group. Kaleebu P, et al. PLoS One. 2015 Dec 23;10(12):e0145536. doi: 10.1371/journal.pone.0145536. eCollection 2015. PLoS One. 2015. PMID: 26700639 Free PMC article.
Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda.
Ssemwanga D, Asio J, Watera C, Nannyonjo M, Nassolo F, Lunkuse S, Salazar-Gonzalez JF, Salazar MG, Sanyu G, Lutalo T, Kabuga U, Ssewanyana I, Namatovu F, Namayanja G, Namale A, Raizes E, Kaggwa M, Namuwenge N, Kirungi W, Katongole-Mbidde E, Kaleebu P; Uganda HIV Drug Resistance Technical Working Group. Ssemwanga D, et al. Among authors: namayanja g. J Antimicrob Chemother. 2020 May 1;75(5):1280-1289. doi: 10.1093/jac/dkz561. J Antimicrob Chemother. 2020. PMID: 32025714 Free PMC article.
Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.
Hamers RL, Oyomopito R, Kityo C, Phanuphak P, Siwale M, Sungkanuparph S, Conradie F, Kumarasamy N, Botes ME, Sirisanthana T, Abdallah S, Li PC, Ngorima N, Kantipong P, Osibogun A, Lee CK, Stevens WS, Kamarulzaman A, Derdelinckx I, Chen YM, Schuurman R, van Vugt M, Rinke de Wit TF; PharmAccess African PASER and TREAT Asia Studies to Evaluate Resistance. Hamers RL, et al. Int J Epidemiol. 2012 Feb;41(1):43-54. doi: 10.1093/ije/dyq192. Epub 2010 Nov 10. Int J Epidemiol. 2012. PMID: 21071386 Free PMC article. No abstract available.
High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021.
Namayanja GA, Da Silva JF, Elur B, Nasirumbi PM, Raizes E, Ssempiira J, Nazziwa E, Nabukenya M, Sewanyana I, Balaba J, Ntale J, Calnan J, Birabwa E, Akao J, Mwangi C, Naluguza M, Ahimbisibwe A, Katureebe C, Nabadda S, Nelson L, Dirlikov E. Namayanja GA, et al. PLoS One. 2024 Jun 26;19(6):e0305129. doi: 10.1371/journal.pone.0305129. eCollection 2024. PLoS One. 2024. PMID: 38923981 Free PMC article.
Factors associated with mortality among people with advanced HIV disease in rural uganda: a retrospective study.
Bwogi K, Lwanira CN, Kasamba I, Baluku JB, Nakiwala JK, Ndagire R, Nassolo C, Wabomba G, Bwanika C, Nakawesi J, Namayanja G, Kabanda J, Kalamya JN, Ssempiira J, Ssenyimba C, Mulebeke R, Fitzmaurice AG, Mukasa B. Bwogi K, et al. Among authors: namayanja g. BMC Infect Dis. 2025 Aug 2;25(1):976. doi: 10.1186/s12879-025-11397-1. BMC Infect Dis. 2025. PMID: 40753372 Free PMC article.
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.
Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, Botes ME, Wellington M, Osibogun A, Sigaloff KC, Nankya I, Schuurman R, Wit FW, Stevens WS, van Vugt M, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER). Hamers RL, et al. Lancet Infect Dis. 2011 Oct;11(10):750-9. doi: 10.1016/S1473-3099(11)70149-9. Epub 2011 Jul 27. Lancet Infect Dis. 2011. PMID: 21802367
Low Levels of Clinically Significant Drug Resistance Mutations to Dolutegravir amongst Children Living with HIV Failing on First-line Antiretroviral Therapy in Uganda.
Magongo EN, Hast M, Nabitaka V, Nakanwagi M, Twinomujjuni E, Dowling S, Senyama G, Nzano B, Alwano M, Nakaweesi J, Nazziwa E, Namayanja G, Nkolo E, Ayitewala A, Hackett S. Magongo EN, et al. Among authors: namayanja g. J Acquir Immune Defic Syndr. 2025 Oct 23. doi: 10.1097/QAI.0000000000003784. Online ahead of print. J Acquir Immune Defic Syndr. 2025. PMID: 41129268
HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022.
Watera C, Da Silva JF, Namayanja G, Asio JN, Ssemwanga D, Pals S, Nabukenya M, Raizes E, Nanyonjo M, Elur B, Nazziwa E, Sanyu G, Ayitewala A, Ssali M, Katureebe C, Balidawa H, Zheng DP, Zeh C, Hackett S, Mwangi C, Naluguza M, Ntale J, Katongole Mbidde E, Kaleebu P. Watera C, et al. Among authors: namayanja g. J Antimicrob Chemother. 2025 Aug 1;80(8):2126-2134. doi: 10.1093/jac/dkaf180. J Antimicrob Chemother. 2025. PMID: 40488412 Free PMC article.
12 results